These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33426634)

  • 1. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.
    Gisondi P; Talamonti M; Chiricozzi A; Piaserico S; Amerio P; Balato A; Bardazzi F; Calzavara Pinton P; Campanati A; Cattaneo A; Dapavo P; De Simone C; Dini V; Fargnoli MC; Flori ML; Galluzzo M; Guarneri C; Lasagni C; Loconsole F; Lo Schiavo A; Malagoli P; Malara G; Mercuri SR; Musumeci ML; Naldi L; Papini M; Parodi A; Potenza C; Prignano F; Rongioletti F; Stingeni L; Tiberio R; Venturini M; Bianchi L; Costanzo A; Cusano F; Girolomoni G; Offidani AM; Peris K
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):235-252. PubMed ID: 33426634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of treatment goals for moderate to severe psoriasis: a European consensus.
    Mrowietz U; Kragballe K; Reich K; Spuls P; Griffiths CE; Nast A; Franke J; Antoniou C; Arenberger P; Balieva F; Bylaite M; Correia O; Daudén E; Gisondi P; Iversen L; Kemény L; Lahfa M; Nijsten T; Rantanen T; Reich A; Rosenbach T; Segaert S; Smith C; Talme T; Volc-Platzer B; Yawalkar N
    Arch Dermatol Res; 2011 Jan; 303(1):1-10. PubMed ID: 20857129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment goals for moderate to severe psoriasis: an Australian consensus.
    Baker C; Mack A; Cooper A; Fischer G; Shumack S; Sidhu S; Soyer HP; Wu J; Chan J; Nash P; Rawlin M; Radulski B; Foley P
    Australas J Dermatol; 2013 May; 54(2):148-54. PubMed ID: 23330815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 6. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.
    Grine L; de la Brassinne M; Ghislain PD; Hillary T; Lambert J; Segaert S; Willaert F; ; Lambert J
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):676-684. PubMed ID: 31749264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
    Carretero G; Puig L; Carrascosa JM; Ferrándiz L; Ruiz-Villaverde R; de la Cueva P; Belinchon I; Vilarrasa E; Del Rio R; Sánchez-Carazo JL; López-Ferrer A; Peral F; Armesto S; Eiris N; Mitxelena J; Vilar-Alejo J; A Martin M; Soria C;
    J Dermatolog Treat; 2018 Jun; 29(4):334-346. PubMed ID: 29099667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PASI90 response: the new standard in therapeutic efficacy for psoriasis.
    Puig L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):645-8. PubMed ID: 25370811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara Pinton P; Chimenti S; Martini P; Peserico A; Puglisi Guerra A; Vena GA;
    J Dermatolog Treat; 2015 Apr; 26(2):128-33. PubMed ID: 24708158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Management of Pediatric Psoriasis: An Italian Consensus.
    Peris K; Fortina AB; Bianchi L; Fabbrocini G; Gisondi P; Balato A; Bardazzi F; Bernardini N; Bonamonte D; Bongiorno MR; Buligan C; Cusano F; Del Giudice MBF; El Hachem M; Fargnoli MC; Gualdi G; Guarneri C; Hansel K; Malara G; Mazzatenta C; Micali G; Narcisi A; Neri I; Oranges T; Panzone M; Parodi A; Restano L; Simonetti O; Venturini M; Di Lernia V
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1753-1775. PubMed ID: 35776408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method.
    Jo SJ; Baek YS; Kim TG; Jeong KH; Kim JE; Choi YS; Kim B; Lee ES; Choe YB;
    Ann Dermatol; 2023 Jun; 35(3):173-182. PubMed ID: 37290951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
    Fargnoli MC; Bardazzi F; Bianchi L; Dapavo P; Fabbrocini G; Gisondi P; Micali G; Offidani AM; Pellacani G; Skroza N; Angileri RG; Burlando M; Campanati A; Carrera CG; Chiricozzi A; Conti A; Simone C; Di Lernia V; Errichetti E; Galluzzo M; Guarneri C; Lasagni C; Lembo S; Loconsole F; Megna M; Musumeci ML; Prignano F; Richetta AG; Trovato E; Venturini M; Peris K; Pinton PC
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients.
    Foley P; Gebauer K; Sullivan J; McMeniman E; Shumack S; Ng J; James A; Rawlin M; Sidhu S; Tilakaratne D; Turner M; Radulski B; Nash P; Baker C
    Australas J Dermatol; 2023 Nov; 64(4):476-487. PubMed ID: 37501636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document.
    Belinchón Romero I; Dauden E; Ferrándiz Foraster C; González-Cantero Á; Carrascosa Carrillo JM
    Ann Med; 2021 Dec; 53(1):1727-1736. PubMed ID: 34601988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Daudén E; Puig L; Ferrándiz C; Sánchez-Carazo JL; Hernanz-Hermosa JM;
    J Eur Acad Dermatol Venereol; 2016 Mar; 30 Suppl 2():1-18. PubMed ID: 26812550
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.